{"id":"NCT04009577","sponsor":"Eisai Inc.","briefTitle":"A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia","officialTitle":"A Multicenter, Pilot Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant for the Treatment of Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-15","primaryCompletion":"2020-03-17","completion":"2020-06-26","firstPosted":"2019-07-05","resultsPosted":"2021-04-12","lastUpdate":"2021-04-12"},"enrollment":53,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Insomnia"],"interventions":[{"type":"DRUG","name":"LEM 5 mg","otherNames":["E2006","Lemborexant"]},{"type":"DRUG","name":"LEM 10 mg","otherNames":["E2006","Lemborexant"]}],"arms":[{"label":"Cohort 1 (LEM 5 mg)","type":"EXPERIMENTAL"},{"label":"Cohort 2A (LEM 5 mg)","type":"EXPERIMENTAL"},{"label":"Cohort 2B (LEM 10 mg)","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the proportion of adult \\[greater than or equal to (\\>=) 18 years\\] participants with insomnia disorder taking zolpidem tartrate immediate release (ZOL-IR) or zolpidem tartrate extended release (ZOL-ER), intermittently or frequently, who transition to lemborexant 5 milligram (mg) (LEM5) or 10 mg (LEM10) after 2 weeks of receiving LEM.","primaryOutcome":{"measure":"Percentage of Overall Participants Who Transitioned to LEM at the End of the Titration Period of Core Study","timeFrame":"Up to 2 Weeks","effectByArm":[{"arm":"Overall Cohort","deltaMin":81.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Somnolence","Abnormal dreams","Accidental overdose"]}}